Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy

Melo, Guilherme Dias de; Hellert, Jan; Gupta, Rajesh; Corti, Davide; Bourhy, Hervé

doi:10.1016/j.coviro.2022.101204

Cited by 37 publications

(35 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the global shortage and high price of HRIG, WHO recommended the use of mAbs as alternatives for RIG in PEP, and to date, several mAbs have been approved or are in clinical trials 43–45 . As an integral part of PEP where vaccination usually takes time to induce an immune response, passive immunization of anti‐RABV mAbs could neutralize RABV and lyse infected cells by ADCC immediately after RABV exposure.…”

Section: Discussionmentioning

confidence: 99%

Development of a reporter gene assay for antibody dependent cellular cytotoxicity activity determination of anti‐rabies virus glycoprotein antibodies

Wang

Cui

et al. 2022

Microbiology and Immunology

View full text Add to dashboard Cite

Rabies is a viral disease that is nearly 100% fatal once clinical signs and symptoms develop. Post-exposure prophylaxis can efficiently prevent rabies, and antibody (Ab) induction by vaccination or passive immunization of human rabies immunoglobulin (HRIG) or monoclonal antibodies (mAbs) play an integral role in prevention against rabies. In addition to their capacity to neutralize viruses, antibodies exert their antiviral effects by antibody-dependent cellular cytotoxicity (ADCC), which plays an important role in antiviral immunity and clearance of viral infections. For antibodies against rabies virus (RABV), evaluation of ADCC activity was neglected. Here, we developed a robust cell-based reporter gene assay (RGA) for the determination of the ADCC activity of anti-RABV antibodies using CVS-N2c-293 cells, which stably express the glycoprotein (G) of RABV strain CVS-N2c as target cells, and Jurkat cells, which stably express FcγRⅢa and nuclear factor of activated T cells (NFAT) reporter gene as effector cells (Jurkat/NFAT-luc/FcγRⅢa cells). The experimental parameters were carefully optimized, and the established ADCC assay was systematically validated according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q2 guideline. We also evaluated the ADCC activity of anti-RABV antibodies, including mAbs, HRIG, and vaccine induced antisera, and found that all test antibodies exhibited ADCC activity with varied strengths. The established RGA provides a novel method for evaluating the ADCC of anti-RABV antibodies.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a reporter gene assay for antibody dependent cellular cytotoxicity activity determination of anti‐rabies virus glycoprotein antibodies

Wang

Cui

et al. 2022

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Compared wtih polyclonal products, Palivizumab provides an increased batch-to-batch stability and a reduced risk of blood-borne pathogen infection with approximately 50-fold enhanced potency (Graham and Ambrosino, 2015). These advantages are also the reasons why mAb drugs are replacing polyclonal antibody products against rabies virus (de Melo et al, 2022), HBV (Cerino et al, 2019) and other pathogens or toxins. Overall, achievements in bioscience, medical science, and bioengineering have accelerated the clinical development of antibody drugs targeting TNF-α, EGFR, CD20, HER2, PD-1/PD-L1 and emerging new molecules (Carter and Lazar, 2018).…”

Section: Introductionmentioning

confidence: 99%

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies

Ling

Yi²,

Sun³

et al. 2022

Sci. China Life Sci.

View full text Add to dashboard Cite

Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been approved in many countries, with most being developed based on the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 has an exceptional ability to mutate under the pressure of host immunity, especially the immune-dominant spike protein of the virus, which is the target of both antibody drugs and vaccines. Given the continuous evolution of the virus and the identification of critical mutation sites, the World Health Organization (WHO) has named 5 variants of concern (VOCs): 4 are previously circulating VOCs, and 1 is currently circulating (Omicron). Due to multiple mutations in the spike protein, the recently emerged Omicron and descendent lineages have been shown to have the strongest ability to evade the neutralizing antibody (NAb) effects of current antibody drugs and vaccines. The development and characterization of broadly neutralizing antibodies (bNAbs) will provide broad strategies for the control of the sophisticated virus SARS-CoV-2. In this review, we describe how the virus evolves to escape NAbs and the potential neutralization mechanisms that associated with bNAbs. We also summarize progress in the development of bNAbs against SARS-CoV-2, human coronaviruses (CoVs) and other emerging pathogens and highlight their scientific and clinical significance.

show abstract

“…Therefore, the use of monoclonal antibody (mAb) to prevent or treat virus-induced infectious diseases is a clear and well-reasoned clinical strategy. This year’s Antiviral Strategies section of Current Opinion in Virology updates the research and development of mAbs against a number of important viruses, including human immunodeficiency virus (HIV) [1] , Ebola virus (EBOV) [2] , Hepatitis B virus (HBV) [3] , influenza virus [4] , coronavirus [5] , human cytomegalovirus (HCMV) [6] , and rabies virus [7] . Moreover, the development of a plant-based platform for producing mAbs against viral infections is also reviewed [8] .…”

mentioning

confidence: 99%

“…HCMV, with a very broad cell tropism, has multiple surface GPs targeting distinct host receptors, while mAbs against these viral GPs (gB, gM/gN complex, gH/gL/gO trimer, and gH/gL/pUL128/130/131 pentamer) are neutralizing [6] . Rabies G protein on the surface of the viral particles, with its ectodomain stabilized by several disulfide bonds, has six antigenic sites (I, IIa, IIb, III, IV, and ‘a’) and is the main target for antirabies neutralizing antibodies [7] . In conclusion, characterization of the Fab region of natural antibodies revealed various neutralizing epitopes on the viral surface proteins and facilitate the elucidation of the molecular mechanisms for neutralization.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses

Wang

Huang²

2022

Current Opinion in Virology

View full text Add to dashboard Cite

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy

Cited by 37 publications

References 64 publications

Development of a reporter gene assay for antibody dependent cellular cytotoxicity activity determination of anti‐rabies virus glycoprotein antibodies

Development of a reporter gene assay for antibody dependent cellular cytotoxicity activity determination of anti‐rabies virus glycoprotein antibodies

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies

Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses

Contact Info

Product

Resources

About